Scarica l'app Stockscreener
27.80
1.14%
-0.32
Dopo l'orario di chiusura:
27.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer stock after-hours at EUR 25.04: minus 0.67 percent - AD HOC NEWS
Pfizer Says Eczema Drug Shows Significant Skin Clearance - Benzinga
Form 4 Pfizer For: 1 October By Investing.com - Investing.com Canada
Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims - WTVB
Florida files lawsuit against Pfizer over COVID-19 vaccineReuters - Українські Національні Новини (УНН)
Does Pfizer (PFE) Have A New Growth Driver In Tilrekimig? - Simply Wall Street
Florida sues Pfizer and CEO Albert Bourla over COVID vaccine claims - Investing.com India
Pfizer Scores Promising Win for Experimental Eczema Drug - Yahoo Finance
Pfizer Sued By Florida AG Over its Covid-19 Vaccine Marketing - Bloomberg Law News
Florida AG sues Pfizer over 'misconduct' related to COVID vaccine risks - Seeking Alpha
Pfizer Sued by Florida Attorney General Over COVID-19 Vaccine Marketing - marketscreener.com
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - Yahoo Finance
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - 247wallst.com
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win - Zacks Investment Research
Pfizer Reports Tilrekimig Phase 2 Atopic Dermatitis Results - grafa.com
Pfizer eczema drug succeeds in mid-stage study (PFE:NYSE) - Seeking Alpha
Pfizer presents tilrekimig data while Pfizer stock stays near its prior close - AD HOC NEWS
Pfizer reports positive phase 2 results for atopic dermatitis drug By Investing.com - Investing.com Canada
Pfizer Inc details 61% EASI‑75 response in tilrekimig trial - Mugglehead Investment Magazine
Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials - insights.citeline.com
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study - Business Wire
Are You Overpaying For Pfizer Stock Versus Its Rivals? - Trefis
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat - Yahoo Finance
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines - Bloomberg Law News
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects? - Yahoo Finance
Pfizer and Moderna Lose Bids to Escape Bayer mRNA Patent Lawsuits - Lawyer Monthly
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough (NYSE:PFE) - Seeking Alpha
Bayer's COVID Vax IP Suits Against Moderna, Pfizer Survive - Law360
Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE) - Seeking Alpha
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit - reuters.com
Pfizer's Tilrekimig Phase 3 Program Seen as Potential Upside Driver, UBS Says - marketscreener.com
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - Yahoo Finance
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? - Yahoo Finance
Pfizer vs. Medtronic: Which Healthcare Turnaround is More Convincing? - Yahoo Finance
Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside? - Yahoo Finance
Pfizer (PFE) Balances Global Pricing Opportunity with New Revenue Sharing - Yahoo Finance
Pfizer Inc. - Britannica
How AI Is Helping Match Patients to Clinical Trials Faster - Pfizer
Pfizer Inc Lobbyists, 2013 - OpenSecrets
Pfizer (NYSE:PFE) Back In Focus As Pricing Deal, Migraine Study, And Vaccine Milestone Shape Its Reset - Kalkine Media
Pfizer (PFE) Bets Big on RSV and Cancer Care - TipRanks
Pfizer: Buy Before The Street Catches Up To Its Own Numbers (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) Targets Air Traffic Fees Over Unpaid Vaccines. Can it Turn a Court Win Into Cash? - Insider Monkey
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? - Yahoo Finance
Pfizer Targets Cancer-Related Weight Loss With New Ponsegromab Study - TipRanks
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
Pfizer stock reports a Q2 earnings beat at USD 28.43 - AD HOC NEWS
Pfizer stock heads into the open after a 0.82 percent gain - AD HOC NEWS
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth? - Yahoo Finance
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost? - Yahoo Finance
Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans (NYSE:PFE) - Seeking Alpha
Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential - TipRanks
What Is Keeping Pfizer Inc. (NYSE:PFE) in the Healthcare Spotlight This September? - Kalkine Media
Pfizer Says It Removed Affected Batches From Market Amid Karnataka Fake Drug Probe - Medical Dialogues
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick? - TradingView
Pfizer stock gains as Q1 profit rises 6.6 percent - AD HOC NEWS
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - theglobeandmail.com
Pfizer Inc. : JP Morgan is Neutral - marketscreener.com
Pfizer (NYSE:PFE) Nears Breakout as Technical Strength and Setup Quality Reach Top Marks - ChartMill
Pfizer stock heads into the open after a 0.23 percent gain - AD HOC NEWS
Pfizer stock ends the day at USD 27.94 at the close - AD HOC NEWS
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):